drugset / Trial / NCT02957890

Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong

NCT02957890

RandomizedParallel-groupTriple-blindPrevention

Summary

This study evaluates the immunogenicity of adding inactivated influenza vaccine with southern hemisphere (SH) formulation to standard once-annual influenza vaccination with northern hemisphere (NH) formulation in older adults in Hong Kong over 9 years. Half of participants will receive twice-annual influenza vaccination with NH and SH formulation, while the other half will receive once-annual influenza vaccination with NH formulation and a placebo.

Timeline

Start
2016-11-18
Primary completion
2025-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject FluQuadri Vaccine 60 ug
Subject FluQuadri Vaccine 0.5 ml
Subject Influenza Virus Vaccine Vaccine 45 ug
Subject Influenza Virus Vaccine Vaccine 0.5 ml

Indications